Biodesix, Inc. (BDSX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Biodesix, Inc. (BDSX)

Go deeper and ask any question about BDSX

Company Performance

Current Price

as of Sep 13, 2024

$1.77

P/E Ratio

N/A

Market Cap

$256.96M

Description

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Metrics

Overview

  • HQLouisville, CO
  • SectorHealth Services
  • IndustryMedical/Nursing Services
  • TickerBDSX
  • Price$1.77-1.67%

Trading Information

  • Market Cap$256.96M
  • Float52.69%
  • Average Daily Volume (1m)95,365
  • Average Daily Volume (3m)135,109
  • EPS-$0.46

Company

  • Revenue$60.90M
  • Rev Growth (1yr)50.99%
  • Net Income-$10.81M
  • Gross Margin78.37%
  • EBITDA Margin-38.22%
  • EBITDA-$6.85M
  • EV$213.87M
  • EV/Revenue3.51
  • P/EN/A
  • P/S3.70